Insufficient scRNA-seq data for expression of LY9 at tissue level.
Tissue | GTEx Coverage  | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 361.66 | 576 / 578 | 62% | 1.61 | 713 / 1155 |
| stomach | 72% | 125.86 | 259 / 359 | 31% | 0.79 | 88 / 286 |
| spleen | 100% | 2552.16 | 241 / 241 | 0% | 0 | 0 / 0 |
| breast | 63% | 209.33 | 289 / 459 | 37% | 0.99 | 414 / 1118 |
| peripheral blood | 100% | 2138.08 | 927 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 10.66 | 28 / 29 |
| thymus | 62% | 149.81 | 406 / 653 | 30% | 1.34 | 183 / 605 |
| kidney | 44% | 112.57 | 39 / 89 | 34% | 0.65 | 310 / 901 |
| liver | 65% | 63.35 | 147 / 226 | 11% | 0.28 | 46 / 406 |
| adipose | 76% | 168.71 | 912 / 1204 | 0% | 0 | 0 / 0 |
| intestine | 55% | 386.27 | 534 / 966 | 20% | 0.49 | 105 / 527 |
| bladder | 57% | 110.76 | 12 / 21 | 18% | 0.46 | 90 / 504 |
| prostate | 59% | 77.21 | 145 / 245 | 13% | 0.25 | 65 / 502 |
| tonsil | 0% | 0 | 0 / 0 | 64% | 2.07 | 29 / 45 |
| skin | 26% | 19.53 | 472 / 1809 | 37% | 1.42 | 175 / 472 |
| uterus | 38% | 28.54 | 65 / 170 | 23% | 0.49 | 106 / 459 |
| esophagus | 25% | 27.72 | 361 / 1445 | 21% | 0.52 | 39 / 183 |
| pancreas | 5% | 3.06 | 15 / 328 | 37% | 1.10 | 65 / 178 |
| blood vessel | 30% | 53.96 | 396 / 1335 | 0% | 0 | 0 / 0 |
| ovary | 17% | 15.93 | 31 / 180 | 9% | 0.14 | 37 / 430 |
| heart | 10% | 15.47 | 90 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 9% | 5.38 | 22 / 258 | 2% | 0.02 | 4 / 230 |
| eye | 0% | 0 | 0 / 0 | 8% | 0.13 | 6 / 80 |
| brain | 2% | 1.23 | 48 / 2642 | 1% | 0.02 | 7 / 705 |
| muscle | 1% | 0.85 | 7 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0007155 | Biological process | cell adhesion |
| GO_0072540 | Biological process | T-helper 17 cell lineage commitment |
| GO_0042110 | Biological process | T cell activation |
| GO_0032740 | Biological process | positive regulation of interleukin-17 production |
| GO_0045087 | Biological process | innate immune response |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0003674 | Molecular function | molecular_function |
| Gene name | LY9 |
| Protein name | Lymphocyte antigen 9 LY9 protein T-lymphocyte surface antigen Ly-9 (Cell surface molecule Ly-9) (Lymphocyte antigen 9) (SLAM family member 3) (SLAMF3) (Signaling lymphocytic activation molecule 3) (CD antigen CD229) |
| Synonyms | CDABP0070 |
| Description | FUNCTION: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A . Promotes recruitment of RORC to the IL-17 promoter . May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4(+) T-cells. May negatively regulate the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells (By similarity). . |
| Accessions | Q0VAI0 Q9HBG7 Q05CA2 Q9UIB4 V9GY30 Q5VYH9 ENST00000368037.9 [Q9HBG7-2] Q5VYI1 ENST00000474998.1 Q9UIB5 A0A0C4DFU4 ENST00000368039.2 ENST00000368035.1 R4GNG7 ENST00000490902.1 ENST00000263285.11 [Q9HBG7-1] ENST00000392203.8 |
